Assess whether scientific advice should be sought before the next trial

SITUATION 505(b)(2) literature-to-product bridge table arrived with a pediatric ethicist objecting to the proposed design for CMC change-control owner. That is a Pharma & Life Sciences CMC and Development Pathways decision on scientific advice should be in a rare-disease team designing a pediatric plan.

DECISION CMC change-control owner in a rare-disease team designing a pediatric plan must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after a pediatric ethicist objecting to the proposed design.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; 505(b)(2) literature-to-product bridge table already has the discriminator after a pediatric ethicist objecting to the proposed design. 2. Keep Pause the pathway in force until 505(b)(2) literature-to-product bridge table is completed after a pediatric ethicist objecting to the proposed design for CMC change-control owner. 3. Treat 505(b)(2) literature-to-product bridge table as Escalate safety review because both readings appear after a pediatric ethicist objecting to the proposed design. 4. Refuse a Pharma & Life Sciences close: CMC change-control owner does not have the decision scientific advice should be turns on in 505(b)(2) literature-to-product bridge table.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a rare-disease team designing a pediatric plan. 2. Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after a pediatric ethicist objecting to the proposed design. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read 505(b)(2) literature-to-product bridge table against a pediatric ethicist objecting to the proposed design and write the one fact that would move scientific advice should be for CMC change-control owner.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (505(b)(2) literature-to-product bridge table after a pediatric ethicist objecting to the proposed design). The follow-on CMC and Development Pathways action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on scientific advice should be, then the evidence in 505(b)(2) literature-to-product bridge table, then the action for CMC change-control owner - Hypothesis scorecard against 505(b)(2) literature-to-product bridge table: supported / rejected / untestable - What changes scientific advice should be if a pediatric ethicist objecting to the proposed design is later withdrawn - Named option among Proceed under protocol, Pause the pathway, Escalate safety review and the fact that kills the others